Phase IIB dose response and safety study of topical formulations of methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the treatment of fingernail psoriasis

MediQuest Therapeutics, Inc. (USA)0 个研究点目标入组 83 人开始时间: 2008年4月24日最近更新: 2019年3月25日

试验速览

暂无简介。

•1. Diagnosed moderate fingernail psoriasis of at least two fingernails
•2. Stable and unchanged psoriasis therapies for two months and must not have received methotrexate for three months prior to screening
•3. Female patients who are not five years post menopausal or surgically sterile must use appropriate birth control for specified time periods and have negative pregnancy tests
•4. 18 - 75 years of age and either sex

•1. Target or control fingernails that are thicker than 2 mm, abnormal or infected (bacterial or fungal)
•2. Patients with immunosuppression, human immunodeficiency virus (HIV), or neuropathies of the hand
•3. Use of any methotrexate preparation, any topical anti-psoriatic medications or ultraviolet treatment within two months of study visit one
•4. Use of more that one two-week course of oral corticosteroid therapy or one injection during three months prior to the screening visit
•5. Use of manicures or cosmetic nail products during and within seven days of the start of treatment
•6. Use of any drug known to have potential for toxicity to a major organ during and within 90 days prior to the start of treatment
•7. Patients who are nursing, pregnant or plan to become pregnant or father a child within the study time frame including within three months of the last dose of study medication

发起方

MediQuest Therapeutics, Inc. (USA)